Active-ingredient Dossier
Risperidone
Active-ingredient Dossier for Risperidone (atypical antipsychotic). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: APO-RISPERIDONE
- Brand: RISPERDAL
- Brand: RISVAN
- Brand: UZEDY
- Brand: RISPERIDONE SANDOZ
- Brand: RISPA
- Therapeutic area: Psychiatry
What is
Risperidone Risperidone is an atypical antipsychotic.
Australian brands containing
Risperidone — APO-RISPERIDONE — RISPERDAL — RISVAN — RISPERIDONE SANDOZ — OZIDAL — RISPA — RISPERIDONE — RISPERNIA — RIXADONE — AURO-RISPERIDONE
Therapeutic areas
Risperidone is registered in neurology, with 19 brands containing this ingredient on the ARTG.
Sponsor landscape
Risperidone is marketed by 12 sponsors, including Arrotex Pharmaceuticals, Sun Pharma, Boucher & Muir, Strides Pharma Science, Janssen-Cilag and Lupin.
PBS and regulatory activity
Three brands containing risperidone have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2016–17 financial year, government expenditure on risperidone was approximately AUD 36.3 million across 532,173 scripts. The latest PBAC outcome for risperidone was recorded on 1 March 2024, with 2 brands having PBAC outcomes on record and no AusPARs on record.